Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2015-06-16 16:19:42
Reporting Period:
Filing Date:
Accepted Time:
2015-06-16 16:19:42
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
744218 Celldex Therapeutics Inc. CLDX In Vitro & In Vivo Diagnostic Substances (2835) 133191702
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1255348 W Avery Catlin C/o Celldex Therapeutics, Inc.
53 Frontage Road
Hampton NJ 08827
Sr. Vp & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-06-15 25,000 $8.52 49,609 No 4 M Direct
Common Stock Disposition 2015-06-15 25,000 $24.59 24,609 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option Disposition 2015-06-15 25,000 $0.00 25,000 $8.52
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2010-01-06 2019-01-06 No 4 M Direct
  1. The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12,2015. The options exercised and sold by the Reporting Person were due to expire January 6,2019.
  2. 25% of the shares vested on January 6, 2010 and the remainder vested quarterly (in equal amounts) over the subsequent 12 quarters.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.35 to $25.23, inclusive. The Reporting Person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.